IBio Spikes After Announcing MUC16 As Target For Immune-Oncology Program

iBio, Inc. (IBIO) shares are surging on Friday morning trade after announcing the disclosure of MUC16 as the target of its latest immune-oncology program for several types of solid tumors, including ovarian, lung, and pancreas cancers.

Currently, shares are at $1.51, up 102.34 percent from the previous close of $0.75 on a volume of 39,997,435.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT